In addition to traditional pathological factors (such as nodal stage, presence of metastasis and tumour grade), determining the presence of molecular markers (CYTH3 and S100A14) may allow us to more adequately assess a patient’s risk of developing chemoresistance in ovarian cancer. Here, S100A14 is linked to neoplasm.